Demographic and clinical characteristics of patients who completed treatment with delamanid in Latvia (July 2014 to August 2016) (n=19)
| Patient | Age years | Sex | Resistance classification | Drug resistance | Previous treatment history | Delamanid treatment duration in months (weeks) | Total MDR-TB treatment duration in months | Companion drugs | Final treatment outcome at the end of MDR-TB treatment |
| 1 | 30 | M | Pre-XDR | H, R, E, Z, Am, Km, Cm, PAS | Z, Cm, Mfx, Pto, Trd, PAS | 9 (36) | 14 | Z, Cm, Mfx, Pto, Trd | Cured |
| 2 | 63 | M | MDR | H, R, E | Z, Cm, Lfx, Pto, Trd, PAS | 6 (24) | 16 | Z, Lfx, Pto, Trd | Cured |
| 3 | 56 | M | XDR | H, R, E, Am, Km, Cm, Ofx, Lfx, Trd, low-dose Mfx | H, R, E, Z | 11 (44) | 0 | Mfx, Lzd, Pto, Amx/Clv | Cured |
| 4 | 62 | M | Pre-XDR | H, R, E, Z, Am, Km, Cm, Pto, Trd | No prior treatment | 10 (40) | 13 | Z, Mfx, Lzd, PAS | Cured |
| 5 | 66 | M | Pre-XDR | H, R, E, Z, Cm, Pto, PAS | No prior treatment | 9 (36) | 12 | Z, Am, Lfx, Lzd, Trd | Cured |
| 6 | 44 | M | Pre-XDR | H, R, E, Z, Am, Km, Cm, Pto | Z, Mfx, Pto, Trd, PAS | 10 (40) | 16 | Lfx, Lzd, Trd, Amx/Clv | Lost to follow-up |
| 7 | 25 | M | XDR | H, R, E, Z, Am, Cm, Mfx, Pto | Trd, PAS, Lzd, Bdq, Amx/Clv | 3 (12) | 18 | Trd, PAS, Amx/Clv | Cured |
| 8 | 56 | M | XDR | H, R, E, Z, Km, Ofx, Lfx, PAS, low-dose Mfx | H, R, E, Z | 9 (36) | 0 | Z, Cm, Mfx, Pto, Trd | Cured |
| 9 | 22 | M | XDR | H, R, E, Z, Cm, Ofx, Lfx, Mfx, PAS | E, Z, Cm, Lfx, Pto, Trd | 6 (24) | 7 | Z, Am, Mfx, Lzd, Pto, Trd | Lost to follow-up |
| 10 | 25 | M | XDR | H, R, Z, Km#, Cm#, Ofx, Lfx, Mfx, PAS | H, R, E, Z | 9 (36) | 14 | Z, Am, Lzd, Pto, Trd | Cured |
| 11 | 48 | M | XDR | H, R, E, Z, Am, Km, Cm, Ofx, Lfx, low-dose Mfx, Pto, Trd, PAS | No prior treatment | 13 (52) | 13 | Mfx, Lzd, PAS, Imp/Cls, Amx/Clv | Cured |
| 12 | 13 | F | Pre-XDR | H, R, E, Am, Km, Cm, Pto | No prior treatment | 6 (24) | 11 | Z, Cm, Mfx, Trd, Amx/Clv | Cured |
| 13 | 56 | M | Pre-XDR | H, R, E, Z, Ofx, Lfx, low-dose Mfx, Pto, PAS | No prior treatment | 14 (58) | 0 | Mfx, Lzd, Trd, Amx/Clv | Cured |
| 14 | 11 | F | XDR | H, R, E, Z, Am, Km, Ofx, Lfx, low-dose Mfx, Pto | No prior treatment | 6 (24) | 0 | Z, Cm, Mfx, Lzd, Trd | Cured |
| 15 | 35 | M | XDR | H, R, E, Z, Cm, Ofx, Lfx, Mfx, Pto, PAS | Z, Am, Pto, Trd, Lzd, Amx/Clv | 11 (44) | 19 | Z, Am, Lzd, Trd, Amx/Clv | Cured |
| 16 | 53 | M | MDR | H, R, E, Z, | E, Z, Lfx, Pto, Trd, PAS | 2 (7) | 12 | Z, Lfx, Lzd, Pto, Trd | Lost to follow-up |
| 17 | 27 | F | Pre-XDR | H, R, E, Z, Ofx, Lfx, Mfx, Pto | Am, Mfx, Trd, Lzd, Amx/Clv | 6 (24) | 18 | Am, Lzd, Trd, Amx/Clv | Cured |
| 18 | 61 | M | Pre-XDR | H, R, E, Z, Am, Km, Cm, PAS | Mfx, Pto, Trd, Amx/Clv | 6 (24) | 19 | Lfx, Lzd, Pto, Trd | Cured |
| 19 | 36 | F | XDR | H, R, E, Z, Am, Km, Cm, Ofx, Lfx, Mfx, Pto, Trd, PAS | Trd, Lzd, Bdq, Amx/Clv, Imp/Cls | 3 (12) | 16 | Lzd, Imp/Cls, Amx/Clv | Cured |
Cured: treatment completed as recommended by the national policy without evidence of failure, and three or more consecutive cultures taken at least 30 days apart are negative after the intensive phase. TB: tuberculosis; MDR: multidrug-resistant; XDR: extensively drug-resistant; H: isoniazid; R: rifampicin; E: ethambutol; Z: pyrazinamide; Am: amikacin; Km: kanamycin; Cm: capreomycin; PAS: para-aminosalicylic acid; Mfx: moxifloxacin; Pto: protionamide; Trd: terizidone; Lfx: levofloxacin; Ofx: ofloxacin; Lzd: linezolid; Amx: amoxicillin; Clv: clavulanate; Bdq: bedaquiline; Imp: imipenem; Cls: cilastatin. #: inconsistent susceptibility test results.